Back to all assets

EssilorLuxottica EL

equity

Price History

€13.45€114.74€216.02€317.3
1999-12 · DCA start€13.66

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-48.5%-32.3%-16.2%0.0%
1999-122026-08 · -48.5%

Worst drawdown: −48%, peaking Sep 2025 and bottoming Aug 2026 — still unrecovered after 11 months.

DCA Backtest

Invested
€32,100
Value today
€114,827
Return
+257.7%
Months invested
321

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be €43,119 today, so the real (inflation-adjusted) return is +166.3%.

Lump sum instead — €32,100 all at once in Dec 1999: €384,083 (+1096.5%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Sep 2025): €965.55 on €1,200 invested (-19.5%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1999-12: +257.7%

About EssilorLuxottica

EssilorLuxottica SA is a Franco-Italian vertically integrated multinational holding company registered in Charenton-Le-Pont and headquartered both in Paris and Milan. It designs, produces and markets ophthalmic lenses, equipment and instruments, prescription glasses and sunglasses. It was founded on 1 October 2018, and its name is an amalgamation of the two major corporations which merged to create it; the French Essilor and the Italian Luxottica. The two companies have, since the merger, been restructured as subsidiaries of the new entity. (Wikipedia)

It's a listed company categorised under health care.

It rates Low Risk at 1.6/5, meaning the rated factors look benign — steady pricing, deep liquidity, and no obvious structural red flags.

What pushes the score up: sector / regulatory (3.0/5).

Scoring well: governance at 1.0/5.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Low Risk(1.6/5)100% rated

How these ratings work

Market / Volatility1.7/5 · weight 20%
  • Annualised volatility (3yr)2/523.5
  • Max drawdown from ATH2/548.5
  • Beta vs S&P 5001/50.10
Liquidity2.0/5 · weight 15%
  • Avg daily $ volume2/599.7m
  • Float % of shares outstandingnot yet researched
Leverage / Financial1.5/5 · weight 20%
  • Debt / equity2/50.37
  • Interest coverage (EBIT / interest)1/511.2
Earnings Quality1.0/5 · weight 15%
  • 3yr EPS volatility1/54.1
Concentration1.0/5 · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentration1/5diversified
Governance1.0/5 · weight 10%
  • Board independence %not yet researched
  • Share structure1/5single class
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.